New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS

RegulatoryapprovedMinjuvirituximablenalidomidePositive

AI Analysis

Summary

Minjuvi (tafasitamab) in combination with rituximab and lenalidomide has been listed on the Pharmaceutical Benefits Scheme as the first and only chemotherapy-free CD19/CD20 dual-targeted immunotherapy regimen for adults with relapsed or refractory follicular lymphoma.

Outcome Details

Listed on the Pharmaceutical Benefits Scheme (PBS) as first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen for adults with relapsed or refractory follicular lymphoma

Importance:7/10

Sentiment:

0.80

immunotherapylymphomaPBS listingregulatory approvalchemotherapy-freecombination therapy

Related Companies

$TRAX

Read the original article

Published by PR Newswire Biotech on August 2, 2026 2:01 PM

Read Original